Discovery and Applied Research for Technological Innovations to Improve Human Health
Active
- Assistance listing
- 93.286
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- 8,568 $9,271,587,462 in federal obligations
Program facts
- Assistance types
-
- Project Grant
- Cooperative Agreement
- Block Grant
- Treasury account
-
- 75-0898-0-1-552
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is funding hypothesis-, design-, technology-, or device-driven research related to discovery, design, development, validation, and application of technologies for biomedical imaging and bioengineering, including biomaterials, Assistance Listing 93.286, with the most recent grant award disbursed on February 1, 2027.
The program remains highly active. Over the past five years (2023–2027), the portfolio has generated 220 to 248 awards annually, with a five-year trend showing modest decline from 248 awards in 2023 to 220 in 2026 and 7 awards in early 2027. The program's funding history spans back to 1976, demonstrating sustained institutional commitment. Recent grant opportunities have been posted, including PAR-27-105 (National Centers for Biomedical Imaging and Bioengineering, forecast only) and multiple companion NOFOs supporting training, translational development, and commercialization pathways.
Funded research encompasses a diverse portfolio spanning biomedical imaging modality development, medical device innovation, and bioengineering tools. Recent awards illustrate this scope: accelerated MRI reconstruction using mixed-precision hardware ($79 thousand), electrical stimulation design for hypertension treatment ($43.9 thousand), bedside tissue oximetry systems for cancer diagnosis ($76.8 thousand), surgical guidance systems for total hip arthroplasty ($50.1 thousand), radiopharmaceutical development for cancer therapy ($76.8 thousand), patient-specific MRI safety prediction using AI ($45.7 thousand), and machine-learning frameworks for therapeutic protein manufacturing ($100.2 thousand). Larger awards include robotic ultrasound systems for acute stroke treatment ($625.6 thousand), next-generation whole-body PET scanner development ($615.6 thousand), fast motion-tolerant pediatric MRI with reduced anesthesia ($636.1 thousand), and highly adhesive sealants for burn surgery hemostasis ($2.01 million).
The program is predominantly Project Grant–driven, accounting for 93 percent of awards (7,928 awards), with smaller shares of Block Grants (6 percent, 482 awards) and Cooperative Agreements (2 percent, 158 awards). Combined federal dollars obligated total $9.27 billion across 8,568 historical awards. The National Institute of Biomedical Imaging and Bioengineering dominates funding concentration, obligating $6.52 billion across 3,248 awards (70 percent of federal dollars), while the broader NIH ecosystem (general NIH funding, Office of the Director, and other institutes including the National Institute of Neurological Disorders and Stroke and National Institute on Aging) accounts for the remaining 30 percent.
Award magnitudes range from under $50 thousand (fellowship and early-stage investigator awards) to multimillion-dollar R01s and Cooperative Agreements. Typical R01 awards cluster between $400 thousand and $750 thousand annually. SBIR and STTR awards span Phase I ($79–314 thousand typically) and Phase II ($552 thousand to $1.09 million observed).
No grant opportunities are currently open with posted application due dates in the immediate term under this Assistance Listing. However, multiple forecast NOFOs signal future funding availability: the National Centers for Biomedical Imaging and Bioengineering (NCBIB) P41 program (PAR-27-105, posted June 9, 2026) and companion programs supporting career development, translational device development, and commercialization readiness (including the SBIR/STTR parent solicitations PA-27-100 and PA-27-102 with April 2027 due dates).
This program remains robust for organizations seeking federal support for imaging technology, biomedical device development, and bioengineering applications. Activity cadence, funding scale, and portfolio diversity indicate stable opportunity for applicants working on hypothesis-driven or technology-driven research within NIBIB's mission.
Objective and description
- Objective
To support hypothesis-, design-, technology-, or device-driven research related to the discovery, design, development, validation, and application of technologies for biomedical imaging and bioengineering. The program includes biomaterials (biomimet
- Description
The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to transform, through technology development, our understanding of disease and its prevention, detection, diagnosis, and treatment. NIBIB supports new tools and technologies to improve human health within its internal laboratories and through grants, collaborations, and training.
Eligibility
- Applicant eligibility
Any corporation, public or private institution or agency, or other legal entity, either nonprofit or for-profit, may apply for a research grant. An applicant for an individual NRSA must be a citizen of the United States or lawfully admitted for permanent residence. Those on temporary or student visas are not eligible. An eligible institution for an institutional NRSA must be capable of providing predoctoral and/or postdoctoral research training opportunities for engineers, bioengineers or other. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit; are not dominant in the field in which research is being proposed; and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the United States or its possessions. To be eligible for funding, a grant application must be reviewed for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. or its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.
- Beneficiary eligibility
Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.
- Uses of assistance
Research Grant funds may be used for salaries, consultation, equipment, travel and other usual costs, subject to Federal regulations applicable to the grant. Individual National Research Service Awards (NRSAs) are made directly to individuals for research training in specified areas related to the mission of NIBIB. Institutional NRSAs may be made to institutions to enable them to accept individuals for research training. Each individual who receives a NRSA postdoctoral fellowship or traineeship is obligated upon termination of the award to comply with certain service and payback provisions. Small Business Innovation Research (SBIR) Phase I grants are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Only Phase I awardees are eligible to apply for Phase II support. Small Business Technology Transfer (STTR) Phase I grants are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of the Phase II application. Indirect costs are paid at negotiated rates for most grant mechanisms. Exceptions are: conference grants (R13 and U13) receive no indirect costs; Training (T), Fellowship (F), and Career (K) awards receive an 8% indirect cost rate; R25 grants receive an 8% indirect cost rate; and SBIR/STTR grants are limited to a 40% indirect cost rate unless the grantee organization negotiates a higher rate.
- Length and time phasing of assistance
Research Grant awards are usually made annually with no project periods to exceed 5 years in length. NRSA Institutional awards may be made for up to 5 years, and Individual awards may be made for up to 5 years at the predoctoral level, 3 years at postdoctoral level, and 2 years at senior level. Normally SBIR and STTR Phase I awards are for 6-12 months and Phase II awards are for up to 2 years.
How to apply
- Criteria for selecting proposals
The major elements in evaluating proposals include assessments of: (1) Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? (2) Approach: Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? (3) Innovation: Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? (4) Investigator: Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? (5) Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? (6) the appropriateness of the proposed budget and duration in relation to the proposed research; (7) the relevance and importance to announced program objectives; (8) the adequacy of plans to include both genders, minorities and their subgroups, and children as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated; (9) the adequacy of the proposed protection for humans or the environment, to the extent they may be adversely affected by the project proposed in the application; and (10) the adequacy of the proposed plan to share data, if appropriate. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for (a)safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.
- Award procedure
All applications for research or training are reviewed for scientific merit by an appropriate initial review group and then by a national advisory council. All applications favorably recommended compete for available funds on the basis of scientific merit and program emphasis. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.
- Time to approval or disapproval
Research Grants: From 6 to 9 months NRSAs: From 6 to 9 months SBIR/STTR: About 7.5 months
- Renewals
Research Grant applications submitted for renewal are reviewed and selected for funding on a competitive basis, as applicable. NRSA awards may be made for 1 to 5 years. No individual may receive more than 5 years of aggregate NRSA support beyond the predoctoral level, and no individual may receive NRSA support for more than 3 years of support beyond the postdoctoral level. Institutional awards may be renewed.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html
Grant opportunities
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Grant awards
Latest 10 of 8,568 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | The General Hospital Corporation | $413,428,045 | 4% |
| 2 | The Johns Hopkins University | $348,496,401 | 4% |
| 3 | The Leland Stanford Junior University | $285,037,155 | 3% |
| 4 | Emory University | $284,592,711 | 3% |
| 5 | Brigham & Womens Hospital Inc. | $238,075,569 | 3% |
| 6 | Massachusetts Institute Of Technology | $199,814,673 | 2% |
| 7 | The Trustees Of The University Of Pennsylvania | $197,042,950 | 2% |
| 8 | The Regents Of The University Of California. San Francisco | $190,822,268 | 2% |
| 9 | Regents Of The University Of Michigan | $175,387,420 | 2% |
| 10 | University Of Washington | $155,259,993 | 2% |
10 of 790 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $360,623,315 |
| FY2025 | $600,317,355 |
| FY2024 | $743,502,141 |
| FY2023 | $780,504,851 |
| FY2022 | $803,347,769 |
| FY2021 | $744,061,276 |
| FY2020 | $596,026,255 |
| FY2019 | $384,003,420 |
| FY2018 | $362,620,487 |
| FY2017 | $326,335,817 |
| FY2016 | $310,350,176 |
| FY2015 | $308,902,113 |
| FY2014 | $286,831,316 |
| FY2013 | $277,831,008 |
| FY2012 | $288,907,960 |
| FY2011 | $269,870,286 |
| FY2010 | $280,835,941 |
| FY2009 | $275,430,313 |
| FY2008 | $141,004,736 |
| FY2007 | $199,991,356 |
| FY2006 | $249,484,992 |
| FY2005 | $258,935,604 |
| FY2004 | $249,905,227 |
| FY2003 | $172,393,741 |
| FY2002 | $39,462,353 |
Show all 25
Quick answers
What is Assistance Listing 93.286?
Assistance Listing 93.286 is Discovery and Applied Research for Technological Innovations to Improve Human Health, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Discovery and Applied Research for Technological Innovations to Improve Human Health?
Its CFDA number is 93.286: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.286 awarded?
8,568 grant awards under 93.286 have obligated $9,271,587,462 in federal funds to 790 recipients.
Who receives the most funding from 93.286?
The recipients obligated the most under Discovery and Applied Research for Technological Innovations to Improve Human Health are The General Hospital Corporation ($413,428,045), The Johns Hopkins University ($348,496,401) and The Leland Stanford Junior University ($285,037,155).
How much did 93.286 obligate in fiscal year 2025?
Grants under 93.286 obligated $600,317,355 in federal funds in fiscal year 2025.
Are there open grant opportunities under 93.286?
33 of the latest 50 opportunities under 93.286 are open or forecasted. The latest, National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional), was posted on June 9, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program